A role for the RUNX genes in cancer fail-safe processes has been suggested by their induction of senescence-like growth arrest in primary murine fibroblasts and the failure of RAS-induced senescence in Runx2-deficient cells. We now show that RUNX1 induces senescence in human primary fibroblasts. High-affinity DNA binding is necessary but not sufficient, as shown by the functional attenuation of the truncated RUNX1/AML1a isoform and the TEL-RUNX1 fusion oncoprotein. However, a similar phenotype was potently induced by the RUNX1-ETO (AML1-ETO) oncoprotein, despite its dominantnegative potential. A detailed comparison of H-RAS V12 , RUNX1 and RUNX1-ETO senescent phenotypes showed that the RUNX effectors induce earlier growth stasis with only low levels of DNA damage signaling and a lack of chromatin condensation, a marker of irreversible growth arrest. In human fibroblasts, all effectors induced p53 in the absence of detectable p14 Arf , whereas only RUNX1-ETO induced senescence in p16
Introduction
The phenomenon of oncogene-induced senescence was first described in primary cultured murine fibroblasts ectopically expressing mutant RAS alleles (Serrano et al., 1997) . It is now generally recognized that this response, similar to apoptosis, represents an important fail-safe process that can protect cells against malignant transformation, a view further supported by functional requirements for the p53 and pRb tumor-suppressor pathways for its execution (Ferbeyre et al., 2002; Narita et al., 2003) . Concerns that this may represent merely an aberrant response to non-physiological cell culture conditions in vitro (Parrinello et al., 2003) have been dispelled by observations that oncogene-expressing or pre-malignant cells can display a similar phenotypic response in vivo (reviewed by Courtois-Cox et al., 2008) . Premature senescence induced by oncogene expression or other stress stimuli resembles the process of replicative senescence described in early studies of long-term culture of primary cells in vitro (Hayflick, 1965) , but differs in that it occurs in young cell cultures and does not reflect telomere attrition. Although most studies of premature senescence have focused on primary fibroblasts, exploiting the advantages of genetic analyses, this phenomenon extends to cells from other lineages (Courtois-Cox et al., 2008) .
The mechanism and downstream pathways involved in RAS-induced senescence have been subject to intense study. Recent studies implicate a DNA damage response secondary to sustained proliferative signaling as a crucial element of RAS-induced senescence (Bartkova et al., 2006; Di Micco et al., 2006) . According to this model, the aberrant expression of oncogenes, such as activated RAS, results in a transient round of cell proliferation, followed by permanent withdrawal from the cell cycle and other phenotypic features indicative of cellular senescence. However, it is clear that the RASinduced stress signaling response is complex and that cell types differ in precise response and genetic requirement, as illustrated by the relative importance of p53 in murine embryonic fibroblasts, whereas p16 Ink4a /Rb pathways predominate in human skin fibroblasts (Brookes et al., 2002) . The ability of the Runx gene family to induce senescence-like growth arrest in primary murine fibroblasts has been described earlier, and this property is shared by all three family members (Linggi et al., 2002; Wotton et al., 2004; Kilbey et al., 2007) . Evidence that the endogenous Runx genes play an intrinsic role in oncogene-induced senescence was provided by the observation that primary mouse embryonic fibroblasts (MEFs) lacking functional Runx2 fail to undergo senescence and are readily transformed by activated RAS V12 (Kilbey et al., 2007) . Runx2 deficiency also leads to loss of senescence in the osteoblast lineage (Zaidi et al., 2007) , whereas an analogous role for Runx1 in hemopoietic progenitors is suggested by the failure of N-RAS-induced growth suppression in cells lacking Runx1 (Motoda et al., 2007) .
In light of the emerging role of Runx proteins in senescence-like growth arrest, we were interested in extending these observations to primary human diploid fibroblasts that have been used extensively in the study of RAS-induced senescence. We also wished to explore the capacity of the common RUNX1 oncoprotein fusion derivatives to modulate this fail-safe mechanism. The RUNX1-ETO fusion arises as a consequence of the t(8;21) chromosomal translocation, and is a frequent feature of acute myeloid leukemia (AML). RUNX1-ETO, a chimeric protein that lacks the transactivation domain of RUNX1, is fused to a transcriptional repressor, ETO, and has dominant-negative activity with respect to wild-type RUNX1 in a variety of transcriptional contexts (reviewed by Blyth et al., 2005) . It is interesting that RUNX1-ETO can repress p19
Arf , an upstream effector of p53, which is required for RUNX1-induced senescence in murine embryonic fibroblasts (Linggi et al., 2002) . TEL-RUNX1, which arises from the t(12;21) fusion in childhood pre-B acute leukemias, is an N-terminal fusion that retains almost all of the RUNX1 reading frame fused to a truncated ETS family protein TEL(ETV6). It also has a dominantnegative activity with regard to the wild-type RUNX1 gene on selected target promoters (Hiebert et al., 1996) .
In this study, we have found that RUNX1 is a potent inducer of senescence-like growth arrest in primary human fibroblasts, but more surprisingly, the RUNX1 fusion proteins are divergent in this respect, having either gained (RUNX1-ETO) or lost potency (TEL-RUNX1) in relation to wild-type RUNX1. Moreover, premature senescence induced by the RUNX mediators differs markedly from RAS-induced senescence, with implications for its potency as a cancer fail-safe mechanism.
Results

RUNX1
induces senescence-like growth arrest, a property that is intensified in RUNX1-ETO but attenuated in TEL-RUNX1 The ectopic expression of each of the three Runx genes in primary murine fibroblasts (MEFs) was earlier shown to induce senescence-like growth arrest by a p53-dependent mechanism (Wotton et al., 2004; Kilbey et al., 2007) . As this phenomenon had not been examined in human fibroblasts, which have distinct genetic requirements for RAS-induced senescence (Gil and Peters, 2006) , we tested this further by expressing RUNX1 in human primary foreskin fibroblasts (Hs68) that have been used extensively to study the requirements for RAS senescence (Brookes et al., 2002) . As shown in Figure 1 , we found that ectopic RUNX1 expression in these cells induced growth arrest with early onset and a senescence-like morphology with a flatter appearance than that seen with H-RAS V12 , similar to earlier observations in MEFs (Wotton et al., 2004) . To determine the structural features of RUNX1 required for this activity, we examined several mutants disrupted in key functional domains. Mutants in DNA binding (K83N) or CBFb cofactor interaction (T161A) (Cammenga et al., 2007) were unable to induce the senescent phenotype and transduced cells appeared virtually indistinguishable from controls. The short RUNX1 (AML1a, 1-250) isoform, which lacks the C-terminal transactivation and inhibitory domains of RUNX1 (Tanaka et al., 1995) , was similarly impaired in senescence potential, indicating that RUNX1 has to bind DNA with high affinity and modulate gene expression to induce senescence-like growth arrest.
The activity of RUNX1 fusion oncoprotein derivatives was also of interest, as both RUNX1-ETO and TEL-RUNX1 have a dominant-negative activity with regard to wild-type RUNX (Lutterbach et al., 2000) . We were surprised to find that RUNX1-ETO also induced growth arrest and senescence in Hs68 cells, with a flatter morphology and intense staining for senescence-associated b-galactosidase. A deletion mutant of RUNX1-ETO, which is essentially devoid of transcriptional repression activity , was inactive. A further surprise was that the TEL-RUNX1 fusion protein, which includes an essentially full-length RUNX1 moiety, lacked the ability to induce senescence-like growth arrest.
As Runx senescence in murine fibroblasts entails a potent induction of p53 and is p53 dependent for execution, we explored the possible similarity between these phenotypes and the ectopic expression of p53 in Hs68 cells. Although p53 also induced significant growth arrest, the cells were less flat and enlarged, particularly in comparison with RUNX1-ETO, and the intensity of cytoplasmic SA-b-Gal staining was less pronounced (Figure 1) . Essentially, similar observations were made in an embryonic lung fibroblast line, TIG3 (Brookes et al., 2002) , which displayed a strong senescence-like growth arrest induced by both RUNX1 and RUNX1-ETO (not shown).
RUNX1 and RUNX1-ETO arrest cell growth more rapidly than does H-RAS V12 and display distinctive patterns of induction of senescence markers The growth arrest induced by both RUNX1 and RUNX1-ETO occurred earlier and was more profound than for H-RAS
V12
, with RUNX1-ETO cells displaying the lowest uptake of BrdU (Figure 2a ). RAS and RUNX1 arrested cells mainly in a 2N state, consistent with G1 arrest, whereas a greater proportion of RUNX1-ETO cells was arrested with 4N DNA content. This phenomenon correlated with a greater proportion of binucleate cells, suggesting a failure of cytokinesis. RUNX1-and RUNX1-ETO-expressing cells lacked the initial growth phase seen in RAS cells during the first 3 days after selection (Figure 2b ). An analysis of markers of senescence-associated growth inhibition (Figure 2d) showed that p53 was induced in all cases, although RAS and RUNX1-ETO cells displayed more potent induction. This was primarily a posttranscriptional response, as quantitative real-time PCR analysis showed a modest induction in Trp53 transcript levels for RUNX1-ETO, but not for RAS V12 or RUNX1 (Figure 2e ). An examination of the levels of p21
WAF1
showed an interesting phenomenon, as RUNX1 and RUNX1-ETO seemed, respectively, to increase or attenuate the induction of this cdk inhibitor relative to its upstream regulator, p53. This effect was highlighted by comparison with RAS V12 , which was, as expected, a strong inducer of p53 and p21 WAF1 (Serrano et al., 1997; Ferbeyre et al., 2002) . Induction of p16
Inka was observed in all cases, but was much stronger in RAS V12 cells and was the weakest in RUNX1-ETO cells. Basal expression of p14 ARF was undetectable in Hs68 s68 cells and was not induced by RAS as noted earlier (Brookes et al., 2002) . It was similarly undetectable in cells expressing RUNX1 or RUNX1-ETO ( Figure 2c ).
As Runx2À/À MEFs display a loss of RAS-induced senescence, which is associated with failure to downregulate G2/M cyclin expression (Kilbey et al., 2007 , we considered the possibility that ectopic RUNX expression might induce growth arrest by repressing the transcription of the same genes. As shown in Figure 2d , RAS-expressing cells showed reduced expression of cyclin A2 and B1, whereas neither of these transcripts was significantly downregulated in day 7 cultures of RUNX1-and RUNX1-ETO-expressing cells.
A closer examination of the various senescent phenotypes also showed a marked difference between RAS V12 and the RUNX mediators, as only the RAS senescent cells displayed evidence of chromatin condensation or senescence-associated heterochromatin foci (SAHF) , as indicated in Figure 3 , by DAPI (4 0 ,6 0 -diamidino-2-phenylindole) staining (middle panel). The presence of SAHFs, specifically in RAS V12 cells, was also confirmed by immunostaining for K9 methylated histone H3 and heterochromatin protein 1g (not shown). Moreover, only the RAS-expressing cells showed organized foci of DNA damage as detected by immunostaining for phosphorylated histone H2AX, a
RUNX1 ( RUNX1 fusion oncoproteins and premature senescence K Wolyniec et al sensitive marker of double-stranded DNA breaks (lower panel) (Di Micco et al., 2006) . Indications of punctate staining above background levels were noted in some cells expressing RUNX1 or RUNX1-ETO, but these were clearly much less extensive than those in the RAS V12 cells. Cells ectopically expressing p53 did not display any evidence of SAHF or double-strand breaks above background levels.
RUNX1-ETO senescence in human fibroblasts is highly dependent on p53 but independent of p16
INK4a
To explore the functional requirements for p53 in the various forms of senescence-like growth arrest, Hs68 cells were transduced with HPV16 E6 oncoprotein. E6 expressing wild-type cells showed an obvious growth advantage over cultures expressing the vector only (Figures 4a and b) . After 4 days, these cells were superinfected with retroviruses encoding RUNX1, RUNX1-ETO, H-RAS V12 or control vector (pBabe), and selected with puromycin. The ability of HPV16 E6 to downregulate p53 was confirmed by western blot analysis (Figure 4c ). Consistent with earlier reports (Wei et al., 2001) , p53 inactivation had only a modest effect on H-RAS V12 growth arrest in human primary fibroblasts. RUNX1 growth arrest was partially rescued by E6, although this was statistically significant only at day 10. In contrast, the proliferation of RUNX1-ETO-expressing cells was substantially rescued by E6. b-gal staining of these cells showed only a few blue cells, which may have escaped E6 transduction (not shown). These findings were also explored in primary MEFs, in which RUNX1 has earlier been shown to induce senescencelike growth arrest in a p53-dependent manner (Wotton et al., 2004) . In p53-null MEFs, RUNX1-ETO did not induce senescence-like morphology or SA-b-gal staining (not shown), although a more marked growth delay was induced compared with that in RUNX1 (Figure 4d ). These results suggest that both RUNX1 and RUNX1-ETO also have cell cycle inhibitory effects that are independent of p53, although it is clearly required for the full expression of the senescent phenotype.
The weak induction of p16 INK4a by RUNX1-ETO and the lack of a detectable expression of p14 ARF in these RUNX1 fusion oncoproteins and premature senescence K Wolyniec et al cells suggested that this form of senescence-like growth arrest might be independent of INK4a (CDKN2A). We therefore examined the effects of RUNX1, RUNX1-ETO and RAS V12 in the Leiden strain of human diploid fibroblasts, which are homozygous for a germline deletion in the second exon of CDKN2A. These cells lack functional p16
INK4a and have been shown to be resistant to H-RAS V12 -mediated senescence-like growth arrest (Brookes et al., 2002) . It is interesting that Leiden cells were fully susceptible to RUNX1-ETO-induced senescence, with proliferation block, morphological change and SA-b-Gal staining similar to those in normal fibroblasts. Although RUNX1 and H-RAS V12 caused a moderate growth delay in these cells, they continued to increase from day 6 onwards and displayed no SA-b-Gal activity on day 8 (Figures 5a and b) .
RUNX1-ETO is a potent inducer of reactive oxygen species and p38
MAPK , a central mediator of senescence-like growth arrest As p53 was potently induced by RUNX1-ETO in cells lacking detectable INK4a/ARF expression and without any evidence of substantial DNA damage, we examined other stress-induced pathways that might account for its activation. Reactive oxygen species (ROS) have been reported to be capable of inducing senescence-like growth arrest and to trigger p53 accumulation (Colavitti and Finkel, 2005) . Levels of ROS in Hs68 cells were examined at day 7 after selection by a FACS-based detection of fluorescence emitted by the peroxidesensitive fluorophore, DCF. H-RAS V12 cells displayed high levels of intracellular ROS, consistent with published data (Figures 6a and b) (Lee et al., 1999) . It is interesting that both RUNX1-and RUNX1-ETOexpressing cells were found to have elevated intracellular ROS levels compared with empty vector control cells. A small but statistically significant increase was seen in RUNX1-expressing cells, whereas RUNX1-ETOexpressing cells showed a profound increase equal to or greater than that seen in H-RAS V12 -expressing cells. It has been reported that ROS induction can activate p38 MAPK (Robinson et al., 1999) . Furthermore, in a recent study, it has been shown that p38
MAPK can act as a sensor of ROS and thereby restrict H-RAS V12 -induced tumorigenesis (Dolado et al., 2007) . It was therefore interesting to test whether the p38 MAPK pathway also mediates RUNX1-and RUNX1-ETO-induced senescence. The abilities of RUNX1 and RUNX1-ETO to activate p38 MAPK were examined using a specific antibody that recognizes two phosphorylation sites responsible for p38 MAPK activation (Thr180 and Tyr182). Indeed, western blot analysis on day 7 of the culture period showed that both RUNX1 and RUNX1-ETO induced elevated levels of phospho-p38, with RUNX1-ETO being the more potent agonist, inducing phosphop38 to a similar degree as does H-RAS V12 (Figure 6c) . Notably, the levels of total p38 MAPK remained unaffected (Figure 6c ). Upregulation of phospho-p38 by RUNX1 and RUNX1-ETO correlated closely with the levels of induction of ROS and with the levels of p53 protein accumulation (Figure 2c ) suggestive of a mechanistic link.
Inactivation of p38 MAPK by the inhibitor, SB203580, at least partially rescues senescence induced by H-RAS V12 and oxidative stress-induced senescence (Wang et al., 2002) . The requirement for p38 MAPK in RUNX1-and RUNX1-ETO-induced senescence was investigated using the p38 inhibitor (SB203580). The growth of cells containing vector was unaffected by the presence of 8 mM SB203580. However, the p38 MAPK inhibitor caused a significant increase in the growth rate of RUNX1-ETOexpressing cells (Figures 7a and b) , and fewer cells had a flattened morphology or SA-b-Gal activity (Figure 7c) . A similar effect was observed for H-RAS V12 -expressing cells, again consistent with earlier reports (Wang et al., 2002) . The treatment of RUNX1-expressing cells with SB203580 also resulted in a partial rescue of the growth RUNX1 fusion oncoproteins and premature senescence K Wolyniec et al arrest; however, the effect was clearly less pronounced relative to that of RUNX1-ETO-expressing cells, suggesting that RUNX1 may also activate growth arrest pathways independently of p38 MAPK .
Discussion
This study extends earlier observations on the induction of senescence-like growth arrest by Runx proteins in primary MEFs (Linggi et al., 2002; Wotton et al., 2004; Kilbey et al., 2007) , showing that human fibroblasts are strongly growth inhibited by ectopic RUNX1 expression. Moreover, the fusion oncoprotein derivative, RUNX1-ETO, is even more potent in this regard, despite its dominant-negative activity with regard to wild-type RUNX1 in other contexts . Both RUNX1 and RUNX1-ETO differ from RAS V12 in the early induction of senescence-like growth arrest without an initial replicative phase and high levels of DNA damage. In this regard, their effects resemble ectopic p53 expression, although both RUNX effectors induced a more marked flat phenotype and stronger SAb-gal staining than did p53 alone. Another common feature with ectopic p53 was the lack of induction of SAHF, a phenomenon that has been ascribed to p16
INK4a and a more stable form of growth arrest than that mediated by p53 and its downstream growth-arrest mediator, p21 WAF1 (Beausejour et al., 2003) . A diagram summarizing the similarities and differences in the effects of RUNX1, RUNX1-ETO and H-RAS V12 on key senescence effectors, and outcomes in Hs68 fibroblasts, is presented in Figure 8 .
Although RUNX1 can both activate and repress the transcription of target genes (Blyth et al., 2005) , the fact that senescence-like growth arrest is also induced by RUNX1-ETO, in which the RUNX1 C-terminal domain is replaced by ETO, suggests that transcriptional repression may be a common denominator in their overlapping phenotypic effects. This suggestion is further indicated by the effects of a RUNX1-ETO deletion mutant lacking C-terminal ETO domains and transcriptional repression activity . The activity loss of the truncated RUNX1/AML1a isoform was also consistent with this hypothesis and is noteworthy as this isoform can antagonize full-length RUNX1 and is often overexpressed in human leukemias (Tsuzuki et al., 2007) . The relative inactivity of TEL-RUNX1 in this system was surprising, however, as this fusion derivative contains an essentially full-length RUNX1 protein and has repressor activity in other contexts. The possibility that the engagement of this failsafe mechanism is selectively lost because of the specific properties of the TEL moiety merits further investigation. Although our findings predict that the loss of senescence is likely to be more strongly selected in RUNX1-ETO cancers, it is also possible that these results reflect cell type-specific responses, and it is notable that TEL-RUNX1 has been reported to collaborate with loss of p16 Ink4a /p19
Arf in murine leukemogenesis (Bernardin et al., 2002) .
Although RUNX and RUNX1-ETO senescence are phenotypically similar, we noted some marked differences in the potency of activation of senescence effectors that correlated well with genetic requirements. RUNX1 displayed a relatively modest induction of p53 compared witho RUNX1-ETO, but a markedly higher expression of its downstream effector, p21
WAF1
. It is tempting to speculate that this is because of direct modulation of the p21 WAF1 promoter, which is an established RUNX target that can be regulated independently of p53 (Westendorf et al., 2002) . However, it should be noted that despite the relatively lower level, RUNX1-ETO still led to p21 WAF1 expression above background levels. The greater tendency of RUNX1 and RAS cells to accumulate in G1 was also consistent with this cdk inhibitor expression pattern, as was the lack of requirement for the p16 INK4a function for RUNX1-ETO-induced senescence observed in Leiden cells. The fact that RUNX1-ETO cells are profoundly growth arrested despite the weak induction of the G1 cdk inhibitors, p16
INK4a and p21
, suggests that other inhibitory factors are also induced (shown as ? in Figure 8 ).
It is notable that RUNX1-ETO growth arrest is markedly dependent on p53, as shown by interference with E6 and the resistance of p53-null MEFs to senescence induction. It is also notable that the induction of p53 in human fibroblasts by all three effectors occurs without a detectable expression of p14 ARF , a canonical player in oncogene signaling to p53 in MEFs (Gil and Peters, 2006) . Moreover, RUNX1-and RUNX1-ETO-arrested cells lack the high level of double-strand breaks as seen in RAS-expressing cells ( RUNX1 fusion oncoproteins and premature senescence K Wolyniec et al pointing to another stress-response pathway that does not require active DNA replication. The strong correlation between the induction of p38 MAPK phosphorylation and ROS by RUNX1-ETO is noteworthy in this respect. Although ROS have the propensity to induce DNA damage, the rapid growth arrest and the lack of ongoing DNA replication in Hs68 cells expressing RUNX1-ETO may have masked this potential. Strong induction of ROS, however, may activate p38 MAPK independently through redox regulation of phosphatases (Robinson et al., 1999) . Our results seem at first sight to contrast with observations in primary CD34 cells expressing RUNX1-ETO, which were found to lack evidence of ROS but displayed DNA damage signals and downregulation of a number of DNA repair enzymes (Krejci et al., 2008) . However, as these cells were grown for 5 weeks in culture before analysis, it is conceivable that these discordant observations are attributable to selection for survival rather than to direct RUNX1-ETO regulation, and it is notable that DNA repair enzymes have not emerged as prominent direct targets for Runx regulation in general transcriptome analyses (Wotton et al., 2008) . In future studies, it will therefore be important to compare early responses with RUNX1-ETO in both cell types.
On the evidence presented here, it may be predicted that the growth arrest induced by ectopic RUNX1 and RUNX1-ETO will be more readily reversible than RASinduced senescence, with a greater propensity for cells to survive and acquire collaborating mutations. This prediction is consistent with the effects of ectopic Runx2 expression in murine thymus, which result in the accumulation of a population of nondividing cells (CD8ISP thymocytes) that are predisposed to malignant transformation, collaborating efficiently with loss of p53 or activated Myc (Blyth et al., 2006) . It is also consistent with studies showing that a subset of human CD34 þ hemopoietic precursor cells, transduced with RUNX1-ETO, can survive for extended periods with an elevated expression of p53 and p21
, despite an increased rate of apoptosis (Krejci et al., 2008) . Moreover, a recent study based on a murine model has advanced the interesting hypothesis that induction of p21 WAF1 and cell cycle restriction by RUNX1-ETO may actually be required for leukemogenesis by preventing DNA damage and hence promoting leukemia stem-cell survival (Viale et al., 2009 ). However, a caveat is that this study contradicts earlier observations that loss of p21 WAF1 actually facilitates RUNX1-ETO leukemogenesis (Peterson et al., 2007) .
A further conclusion from our findings in this study is that Runx functions impinge on cellular senescence on several different levels. We have earlier reported that loss of RAS-induced senescence in Runx2À/À MEFs operates at a late stage of the process, as these cells display a full cascade of growth inhibitors but are impaired in their ability to silence G2/M cyclin gene expression (Kilbey et al., 2007 . It is clear that the induction of senescence-like growth arrest by ectopic Runx expression is not the simple mirror image of this process. Although the Runx family is well known for its ability to activate or repress specific target genes (Swantek and Gergen, 2004) , we suggest that their paradoxical oncogenic and tumour-suppressor potential may arise instead from their involvement in distinct steps in cellular growth regulation.
Materials and methods
Cells and retroviral constructs
Hs68 neonatal foreskin fibroblasts and Leiden cells expressing ecotropic MLV receptor have been described earlier (Brookes et al., 2002) . Primary p53-null MEFs were prepared as described (Dolado et al., 2007) . The ecotropic virus-packaging cell line, Phoenix, was obtained from G Nolan, Stanford University, Palo Alto, CA, USA. All cultures were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Paisley, Renfrewshire, UK) plus 10% fetal calf serum, glutamine (2 mM), penicillin (200 U/ml) and streptomycin (100 mg/ml). For pharmacological treatment, SB203580 (Calbiochem, Nottingham, UK) was dissolved in Dulbecco's modified Eagle's medium and added to cultures on the first day after selection (8 mM). The medium with the drug was changed every day. The retroviral vectors used were pBabe-puro and pLXSN-neo. The pBabe puro constructs containing human RUNX1, RUNX1-ETO, RUNX1-ETOD469 and TEL-RUNX1 were described earlier, and kindly supplied by S Hiebert (Linggi et al., 2002) . The pBabe-H-RAS V12 construct has been described earlier and kindly provided by S Lowe (Serrano et al., 1997) . pBabe puro-containing p53 has also been described earlier. The retroviral plasmids containing RUNX1 (1-250) and RUNX1 mutants, K83N and T161A, were constructed by cloning of relevant cDNAs into pBabe puro vectors. pLXSN and pLXSN-E6 were a gift from S Campo (University of Glasgow, UK). Retroviral-mediated gene transfer was carried out as described (Wotton et al., 2004) . Hs68 cells were infected with retroviruses expressing E6 or empty vector (LXSN), and incubated in geneticin (Gibco, Paisley, Renfrewshire, UK, 300 mg/ml). Infected cell populations were then superinfected with retroviruses expressing RUNX1, RUNX1-ETO, H-RAS V12 or empty vector (pBabe), and selected in puromycin 2 mg/ml for 4 days.
Growth curves
Cells were plated at 2.5 Â 10 4 /well in 12-well plates in a selection medium containing 2 mg/ml puromycin. Live cell counts were carried out in triplicate by a hemocytometer and Trypan blue vital staining. Media were changed every 3-4 days. Graphs were plotted using Sigma plot. Error bars relate to standard deviations.
Senescence staining
Senescence staining was assayed using a solution of X-gal (Invitrogen) at pH 6.0 to detect SA-b-galactosidase activity as described (Wotton et al., 2004) .
Immunofluorescence Cells were plated on poly-L-lysine-coated (13.3 mg/ml) glass chamber slides and fixed for 15 min with freshly prepared 4% paraformaldehyde (in phosphate-buffered saline (PBS)). After washing with PBS, the cells were permeabilized for 15 min with PBST (PBS with 0.1% Triton X-100). The cells were then blocked with 10% fetal calf serum, 0.5% bovine serum albumin in PBS for 30 min and incubated overnight at 4 1C with a primary antibody, mouse monoclonal g-H2AX, (1:100, 05-636, Upstate, Dundee, UK), diluted in blocking buffer.
After washing in 10% fetal calf serum and 0.5% bovine serum albumin in PBS, the cells were stained with an FITCconjugated secondary antibody (1:100, Jackson Immuno Research Laboratories, Luton, UK) for 45 min at room temperature. Finally, the cells were washed in PBS and coverslips were mounted in VectaShield containing DAPI (Vector Laboratories, Peterborough, UK). Fluorescent images were captured using a confocal microscope (Leica DM IRE2, Milton Keynes, UK).
Cell cycle analysis
The protocol for cell cycle analysis has been described (Wei et al., 2001) . For simultaneous labeling with bromodeoxyuridine (BrdUrd), cells were incubated at 37 1C for 3-h with 10 mM BrdU (Sigma, Poole, Dorset, UK), then rinsed thrice in warmed PBS. After harvesting, the cells (10 6 ) were washed in 2 ml cold PBS, resuspended in 0.2 ml cold PBS and fixed for at least 30 min in 2 ml 70% ethanol at 4 1C. BrdU incorporation was identified using an FITC-conjugated anti-BrdU antibody (Roche, Welwyn Garden City, UK) according to the manufacturers' instructions. The samples were resuspended in PBS containing 10 mg/ml propidium iodide and visualized on a Beckman Coulter Epics XL, Beckman Coulter, Miami, FL, USA. The analysis was carried out using the manufacturer's EXPO32 software.
Analysis of intracellular ROS
To assess the generation of intracellular ROS levels, cells were incubated for 20 min in the dark at 37 1C with 15 mm DCF-DA (Calbiochem). DCF fluorescence was measured using a flow cytometer (Beckman Coulter Epics XL), with excitation at 488 nm and emission at 530 nm.
Quantitative real-time PCR RNA extraction, cDNA preparation and amplification using primers for human Cyclin A2, Cyclin B1, p53 or endogenous control HPRT (Qiagen Quantitect Primer assays QT00014798, QT00006615, QT00060235 and QT00059066, Qiagen, Crawley, W Sussex, UK) were as described (Kilbey et al., 2007) . Quantification was relative to pBabe puro.
Western blotting and antibodies Cells were washed in cold PBS and whole-cell extracts were prepared in lysis buffer (20 mM HEPES, 5 mM EDTA, 10 mM EGTA, 5 mM NaF, 0.1 mg/ml okadaic acid, 10% glycerol, 1 mM DTT containing 0.4 M KCl, À0.4% Triton X-100 and protease inhibitors; 5 mg/ml leupeptin, 5 mg/ml aprotinin, 5 mg/ml pepstatin A, 1 mM benzamidine, 50 mg/m phenylmethylsulfonyl fluoride). Samples equivalent to 30 mg total protein (Biorad protein assay) were resolved on 8 or 15% SDS-polyacrylamide gels and transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Crawley, Sussex, UK). The following antibodies were used: H-RAS (Oncogene, Nottingham, UK: Ab-1), p16
